Analysts Anticipate Biopharmx Corp (BPMX) Will Announce Quarterly Sales of $30,000.00
Brokerages expect Biopharmx Corp (NASDAQ:BPMX) to announce $30,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Biopharmx Corp’s earnings. The lowest sales estimate is $10,000.00 and the highest is $40,000.00. Biopharmx Corp also reported sales of $30,000.00 in the same quarter last year. The firm is scheduled to announce its next earnings results on Tuesday, December 12th.
According to Zacks, analysts expect that Biopharmx Corp will report full-year sales of $30,000.00 for the current financial year, with estimates ranging from $30,000.00 to $590,000.00. For the next fiscal year, analysts forecast that the business will post sales of $5.07 million per share, with estimates ranging from $50,000.00 to $15.00 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Biopharmx Corp.
Biopharmx Corp (NASDAQ:BPMX) last released its earnings results on Wednesday, September 13th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Biopharmx Corp had a negative return on equity of 1,847.04% and a negative net margin of 28,405.26%.
BPMX has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of Biopharmx Corp in a research note on Wednesday. Maxim Group reissued a “buy” rating and set a $1.50 price target (down previously from $3.00) on shares of Biopharmx Corp in a research note on Wednesday. Finally, Roth Capital set a $3.00 price target on Biopharmx Corp and gave the stock a “buy” rating in a research note on Saturday, June 3rd.
Biopharmx Corp (BPMX) opened at 0.305 on Friday. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $0.90. The stock has a 50 day moving average price of $0.31 and a 200 day moving average price of $0.48. The stock’s market cap is $22.61 million.
In related news, major shareholder Franklin Resources Inc bought 250,000 shares of Biopharmx Corp stock in a transaction that occurred on Tuesday, August 1st. The shares were purchased at an average price of $0.34 per share, with a total value of $85,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
A number of hedge funds have recently bought and sold shares of the stock. Vivo Capital LLC lifted its stake in Biopharmx Corp by 10.0% in the 2nd quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock valued at $6,752,000 after buying an additional 1,282,052 shares in the last quarter. Vanguard Group Inc. lifted its stake in Biopharmx Corp by 324.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock valued at $927,000 after buying an additional 1,478,338 shares in the last quarter. Finally, Virtu KCG Holdings LLC lifted its stake in Biopharmx Corp by 366.2% in the 2nd quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock valued at $241,000 after buying an additional 395,424 shares in the last quarter.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/17/analysts-anticipate-biopharmx-corp-bpmx-will-announce-quarterly-sales-of-30000-00.html.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.